Rescue of SCID murine ischemic hindlimbs with pH-modified rhbFGF/Poly(DL-lactic-co-glycolic acid) implants

Journal of Controlled Release

Volumn 122, Issue 3, 2007, Pages 331-337

  Zhong, Yanqiang ^a   Zhang, Li ^a   Ding, Amy G ^a   Shenderova, Anna ^a   Zhu, Gaozhong ^b   Pei, Ping ^c   Chen, Ruth R ^d   Mallery, Susan R ^c   Mooney, David J ^d   Schwendeman, Steven P ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b SHIRE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d HARVARD UNIVERSITY   (United States)

Author keywords

Angionesis; Ischemia; Poly(lactic co glycolic acid) (PLGA); Protein stability; Recombinant human basic fibroblast growth factor (rhbFGF)

Indexed keywords

BLOOD VESSELS; DISEASES; FIBROBLASTS; PROTEINS; TISSUE;

ANGIONESIS; ISCHEMIA; POLY(LACTIC-CO-GLYCOLIC ACID) (PLGA); PROTEIN STABILITY; RECOMBINANT HUMAN BASIC FIBROBLAST GROWTH FACTOR (RHBFGF);

IMPLANTS (SURGICAL);

EDETIC ACID; GUM ARABIC; HEPARIN; MAGNESIUM HYDROXIDE; POLYGLACTIN; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; STABILIZING AGENT; SUCROSE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLATERAL CIRCULATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG FORMULATION; DRUG STABILITY; ENCAPSULATION; GRANULATION TISSUE; HINDLIMB; IMPLANT; IN VIVO STUDY; ISCHEMIC HEART DISEASE; LIMB ISCHEMIA; MALE; MOUSE; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PH; PRIORITY JOURNAL; REPERFUSION; SCID MOUSE; SURVIVAL;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FIBROBLAST GROWTH FACTORS; HINDLIMB; HUMANS; HYDROGEN-ION CONCENTRATION; ISCHEMIA; LACTIC ACID; MALE; MICE; MICE, SCID; NECROSIS; NEOVASCULARIZATION, PHYSIOLOGIC; POLYGLYCOLIC ACID; POLYMERS; RECOMBINANT PROTEINS; REGIONAL BLOOD FLOW;

EID: 34548619660     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2007.05.016     Document Type: Article

References (35)

1. Schoen F.J. Diseases of the heart. Pathological Basis of Disease (1999), W.B.Saunders Co., Philadelphia, PA 277-304
2. Solomon A.J., and Gersh B.J. Management of chronic stable angina: medical therapy, percutaneous transluminal coronary angioplasty, and coronary artery bypass graft surgery - lessons from randomized trials. Ann. Intern. Med. 128 (1998) 216-223
3. Khurana R., and Simons M. Insights from angiogenesis trials using fibroblast growth factor for advanced artheriosclerotic disease. Trends Cardiovasc. Med. 13 3 (2003) 116-122
4. Post M.J., Laham R., Selleke F.W., and Simons M. Therapeutic angiogenesis in cardiology using protein formulations. Cardiovasc. Res. 49 (2001) 522-531
5. Schumacher B., Pecher P., Von Specht B.U., and Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 97 (1998) 645-650
6. Sellke F.W., Laham R.J., Edelman E.R., Pearlman J.D., and Simons M. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann. Thorac. Surg. 65 (1998) 1540-1544
7. Dor Y., Djonov V., Abramovitch R., Itin A., Fishman G.I., Carmeliet P., et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J. 21 (2002) 1939-1947
8. Lazarous D.F., Shou M., Stiber J.A., Dadhania D.M., Thirumurti V., Hodge E., et al. Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution. Cardiovasc. Res. 36 (1997) 78-85
9. Edelman E.R., Nugent M.A., and Karnovsky M.J. Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. Proc. Natl. Acad. Sci. U. S. A. 90 4 (1993) 1513-1517
10. Whalen G.F., Shin Y., and Folkman J. The fate of intravenously administered bFGF and the effect of heparin. Growth Factors 1 (1989) 157-164
11. Mazue G., Bertoleto F., Jacob C., Sarmines P., and Roncucci R. Preclinical and clinical studies with recombinant human basic fibroblast growth factor. Ann. N. Y. Acad. Sci. 638 (1991) 329-340
12. Mazue G., Newman A.J., Scampini G., Dellatorre P., Hard G.C., Iatropoulos M.J., et al. The histopathology of kidney changes in rats and monkeys following intravenous administration of massive doses of FCE-26184, human basic fibroblast growth factor. Toxicol. Pathol. 21 (1993) 490-501
13. Goncalves L.M., Epstein S.E., and Piek J.J. Controlling collateral development: the difficult task of mimicking mother nature. Cardiovasc. Res. 49 (2001) 495-496
14. Simons M., Annex B.H., Laham R.J., Kleiman N., Henry T., Dauerman H., et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 105 (2002) 788-793
15. Lederman R.J., Mendelsohn F.O., Anderson R.D., Saucedo J.F., Tenaglia A.N., Hermiller J.B., et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomized trial. Lancet 359 (2002) 2053-2058
16. Burgess W.H., and Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. Ann. Rev. Biochem. 58 (1989) 575-606
17. Montesano R., Vassalli J.D., Baird A., Guillemin R., and Orci L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc. Natl. Acad. Sci. U. S. A. 83 (1983) 7297-9301
18. Edelman E.R., Mathiowitz E., Langer R., and Klarboum M. Controlled and modulated release of basic fibroblast growth factor. Biomaterials 12 7 (1991) 619-626
19. Laham R.J., Sellke F.W., Edelman E.R., Pearlman J.D., Ware J.A., Brown D.L., et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 100 (1999) 1865-1871
20. Putney S.D., and Burke P.A. Improving protein therapeutics with sustained release formulations. Nat. Biotechnol. 16 (1998) 153-157
21. Schwendeman S.P., Costantino H.R., Gupta R.K., and Langer R. Peptide, protein, and vaccine delivery from implantable polymeric systems: progress and challenges. In: Park K. (Ed). Controlled Drug Delivery: Challenges and Strategies (1997), Am. Chem. Soc., Washington DC 229-267
22. Cleland J.L., Duenas E.T., Park A., Daugherty A., Kahn J., Kowalski J., et al. Development of poly-(d,l-lactide-coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis. J. Control. Release 72 (2001) 13-24
23. Zhu G.Z., Mallery S.R., and Schwendeman S.P. Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide). Nat. Biotechnol. 18 (2000) 52-57
24. Richardson T.P., Peters M.C., Ennett A.B., and Mooney D.J. Polymeric system for dual growth factor delivery. Nat. Biotechnol. 19 (2001) 1029-1034
25. Wang Y.J., Shahrokh Z., Vemuri S., Eberlei G., Beylin I., and Bush M. Characterization, stability, and formulations of basic fibroblast growth factor. In: Pearlman R., and Wang Y.J. (Eds). Formulation, Characterization, and Stability of Protein Drugs (1996), Plenum Press, New York 141-181
26. Gospodarowicz D., and Cheng J. Heparin protects basic and acidic FGF from inactivation. J. Cell. Physiol. 128 3 (1986) 475-484
27. Shenderova A., Burke T.G., and Schwendeman S.P. The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins. Pharm. Res. 16 (1999) 241-248
28. Zhu G., and Schwendeman S.P. Stabilization of proteins encapsulated in cylindrical poly (lactide-co-glycolide) implants: mechanism of stabilization by basic additives. Pharm. Res. 17 3 (2000) 351-357
29. G. Zhu, Stabilization and controlled release of proteins encapsulated in poly(lactide-co-glycolide) delivery systems, Dissertation 1999. Ohio State University.
30. Lee K.Y., Peters M.C., and Mooney D.J. Comparison of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in SCID mice. J. Control. Release 87 (2003) 49-56
31. Sun Q.H., Chen R.R., Shen Y.C., Mooney D.J., Rajagopalan S., and Grossman P.M. Sustained vascular endothelial growth factor delivery enhances angiogenesis and perfusion in ischemic hind limb. Pharm. Res. 22 (2005) 1110-1116
32. 2 and sucrose on the stability of bovine serum albumin encapsulated in injectable poly(D,L-lactide-co-glycolide) implants. Biomaterials 23 1 (2002) 239-245
33. Jiang W., and Schwendeman S.P. Stabilization of tetanus toxoid encapsulated in PLGA microspheres, Abstract. Proc. Int. Symp. Control. Release Bioact. Mater. 29 (2002) #142
34. Mallery S.R., Pei P., Kang J., Zhu G., Ness G.M., and Schwendeman S.P. Sustained angiogenesis enables in vivo transplation of mucocutaneous derived AIDS-related Kapsosi's sarcoma cells in murine hosts. Carcinogenesis 21 (2000) 1647-1653
35. Jain R.K. Molecular regulation of vessel maturation. Nat. Med. 9 6 (2003) 685-693